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Abstract 
Background: Montelukast is a leukotriene receptor antagonist. The release of leukotrienes causes narrowing and 
constricting in the respiratory airways. Blocking the action of these leukotrienes, montelukast can be used for the 
prophylaxis and treatment of chronic asthma.
Objective: The aim of this study was to evaluate the interchangeability and comparative effectiveness between a 
generic and a brand montelukast 10 mg immediate release tablets (Broncast® and Singulair®, respectively) after a 
single oral dose among Arab Mediterranean volunteers.
Methods: An open-label, randomized two-period crossover bioequivalence design was conducted in 31 healthy 
male volunteers with a 1 week washout between each study period and under fasting conditions. The plasma drug 
concentration was assessed by using a previously validated LC MS/MS method. The ratio between the generic and 
brand of geometric least squares means was reported for both generic and brand products. Moreover, an in vitro 
dissolution study was conducted on generic and brand tablets using three different pH media, and similarity and 
non-similarity factors (f2 and f1) were calculated.
Results: The used bioanalytical method was found to be linear within the range 6.098–365.855 ng/mL. The cor-
relation coefficient was close to 0.999 during the course of the study validation. Statistical comparison of the main 
pharmacokinetic parameters showed the inexistence of any significant difference between generic and the brand. 
The point estimates (ratios of geometric means) were 111.939, 111.711, and 112.169 % for AUC0–24, AUC0–∞, and Cmax, 
respectively. The 90 % confidence intervals (CIs) were within the pre-defined limits of 80.00–125.00 % as specified 
by the FDA and EMA for bioequivalence studies. F2 and f1 were higher than 50 and lower than 15, respectively in all 
selected pH media.
Conclusion: Broncast® immediate release film coated tablets (10 mg/tablet) are bioequivalent to Singulair® immedi-
ate release film coated tablets (10 mg/tablet), with a comparable safety and efficacy profile. This suggests that these 
two formulations can be clinically considered interchangeable. The dissolution study suggests that it could be used as 
premarketing quality control parameter in order to maintain the high quality of the produced product.
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Background
Montelukast (MT) is a photolabile powder with the fol-
lowing IUPAC name: (R,E)-2-(1-((1-(3-(2-(7-chloroqui-
nolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)
phenyl)propylthio)methyl)cyclopropyl) acetic acid [1, 2]. 
MT is a potent; orally administered and active drug with 
anti-inflammatory properties that significantly improves 
asthmatic inflammation factors. It has a great affinity 
and selectivity to CysLT1 receptors over other respira-
tory tract receptors; such as the prostanoid; cholinergic; 
or β-adrenergic receptors. MT specifically inhibits the 
physiological action of LTC4; LTD4; LTE4 leukotrienes 
at CysLT1 receptors without any agonist activity [3–6]. 
Therefore; it is indicated for the prophylaxis and chronic 
treatment of asthma in adults and over 1 year-old pediat-
ric patients; and it helps to control the symptoms of sea-
sonal and perennial allergic rhinitis [4, 7, 8]. It has also 
demonstrated to be effective in the prevention of asthma 
caused by exercise in patients aged above 6 years [9]. Bio-
availability studies showed that the presence of food in 
the GIT does not affect bioavailability parameters when 
an immediate release tablet is given with a standard meal 
[4, 10].
The oral bioavailability of MT when administered as a 
10 mg immediate release (IR) film-coated tablet in adults 
was found to be 58–66  % [1]. In 2012, MT (Singulair®) 
immediate release tablets and other dosage forms includ-
ing granules and chewable tablets were approved by the 
FDA for the treatment of asthma and allergic rhinitis. 
It is usually administered once daily in a dose of 10 or 
5 mg per tablet or granules [11]. In the current study, the 
generic MT immediate release tablets were formulated in 
a single strength (10 mg/tablet). This product was devel-
oped to be as effective, and safe as the original brand. 
Accordingly, the objective of this study was to evaluate 
the bioequivalence of MT tablet formulations (10  mg/
tablet) by comparing its pharmacokinetic parameters 
with the original brand. In addition, the in vivo safety of 
the two formulations (generic and brand) based on clini-
cal and laboratory examinations and documentation of 
any adverse effect was also investigated.
Methods
The study was a comparative, randomized, two-period, 
two-treatment, two-sequence, single dose, open label, 
crossover bioequivalence study of a generic MT 10  mg 
immediate release coated tablets (one tablet) (Ava-
lon Pharma, Middle East pharmaceutical industries Co 
Itd, KSA) Versus Singulair® 10  mg Film-Coated Tablets 
(one tablet) (Merck Sharp and Dohme Limited, Shotton 
Lane, Cramlington, Northumberland, NE23 3JU, UK) 
in healthy Subjects under fasting conditions given to 
healthy subjects under fasting conditions.
Volunteers and clinical protocol
The study was conducted by Arab Pharmaceutical Indus-
try Consulting Co. Ltd./Jordan in accordance with the 
requirements of the declarations of Helsinki [12], the 
current Good Clinical Practice (GPC) Guidelines [13] 
and the International Conference Harmonization (ICH) 
Guidelines [14]. The study protocol and the informed 
consent forms were approved by the Institutional Review 
Board (IRB). The volunteers were aged between 18 and 
50  years, weighing between 57 and 93  kg with an aver-
age weight of 76 kg with body-mass index 18.5–30.0 kg/
m2 inclusive, non-smokers or light smokers (smokers 
of not more than 10 cigarettes per day).The volunteers 
were subjected to a full medical and physical exam to 
confirm their healthy status and were not on any medi-
cation during the study period. The nature of the study 
was explained to the volunteers throughout a written 
informed consent, which was given to each one. The 
volunteers were instructed to abstain from taking drugs 
1 month before starting the study, caffeine and alcohol-
containing beverages for at least 16 h prior to each phase 
of the study and throughout the study period and to fast 
for at least 10 h before MT administration.
The study used an open-label, randomized two-period 
crossover design with a 9-day washout period between 
doses in 32 healthy subjects under fasting conditions. 
Thirty-two healthy adult male volunteers were recruited 
to participate in the study. 31 subjects completed the 
study and 31 subjects were evaluated for pharmacoki-
netic data. One volunteer was excluded by the clinical 
investigator due to an insufficient platelet count. The vol-
unteers were randomly divided into two groups of 16 and 
15 subjects. The first group was given the reference brand 
and the second group was given the test formulation with 
a crossover after the washout period. On the morning of 
the study, each volunteer gave a blood sample to serve 
as a blank for the drug assay. Each volunteer received an 
oral dose of the assigned MT formulation administered 
with 240 mL of water in the sitting position. During each 
period blood samples were collected from each volun-
teer for the calculation of the PK parameters at zero and 
up to 24  h after drug dosing. Each sample volume was 
8  mL, 1  h before dosing, and 8  mL samples were with-
drawn at following time points 0.50, 1.00, 1.50, 1.75, 2.00, 
2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 3.75, 4.00, 5.00, 6.00, 8.00, 
12.00, 16.00 and 24.00 h after dosing. Blood samples were 
collected in tubes containing heparin, and centrifuged to 
separate the plasma fraction of the blood. The resulting 
plasma was immediately stored at −70  °C and analyzed 
by liquid chromatography tandem mass spectrometry 
(LC–MS/MS). Four hours after drug administration a 
standard lunch meal containing soup (no carrots), half a 
chicken, rice with mixed vegetables (no carrots), yogurt, 
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a loaf of bread, salad (tomato and cucumber) was served 
and subjects had free access to water 1  h after drug 
administration.
Chemicals and reagents
MT working standard (99.4 %) was supplied by Morepen 
Laboratories Ltd. (State Hemachal Pradesh, India) while 
the MT-d6 internal standard (97 %) was supplied by TRC 
(North York, Canada). HPLC-grade methanol and ace-
tonitrile were purchased from Romil (Cambridge, UK), 
iso-propanol was obtained from Carbon Group (Cork, 
Ireland), extra pure formic acid was obtained from Schar-
lau (Port Adelaide, Australia), diethylether was obtained 
from JHD (Guangzhou, China) and HPLC grade water 
was supplied by Sartorius Purified Water (Goettingen, 
Germany). Control human plasma was harvested from 
donors.
Tested brand and formulated tablets
The generic tablets, Broncast® immediate release coated 
tablets (10  mg  mg/tablet) were obtained from Avalon 
Pharma, (Middle East Pharmaceutical Industries Co 
Ltd, KSA) batch number 303111. Singulair® immediate 
release coated tablets (10 mg/tablet) were obtained from 
Merck Sharp and Dohme (Northumberland, UK) and 
had a batch number of 322559.
Instruments and chromatographic separations
A simple, fast, selective, accurate and precise High Per-
formance Liquid Chromatographic method (Agilent 
Technologies, Santa Clara, United States) interfaced with 
an API 4000 tandem MS system (AB Sciex, Framingham, 
USA) was used in the analysis for the determination of 
MT in human plasma. The method was validated for its 
application to the analysis of MT in authentic plasma 
samples harvested after a single dose of MT 10  mg IR 
film coated tablets. To complete the present bioequiva-
lence study, sampling lasted for 24.00  h after dosing; 
consequently a limit of quantification was 6.098 ng/mL. 
Montelukast-d6 was employed as the internal standard 
for MT, to perform its function of compensating for assay 
variability in the total analytical process. The station-
ary phase was ACE 5 CN (B2). The column used was an 
ACE 5 CN, 5  cm length and 4.6  mm internal diameter 
(HiChrom, Reading, UK). The mobile phase was com-
posed of acetonitrile; 0.005  M ammonium acetate and 
formic acid in a ratio of 80:20:0.1 (v/v/v), respectively. 
The pH of the mobile phase was 4.30 ±  0.2. The injec-
tion volume was 10 µL and the flow rate was 0.80  mL/
min. 100 % methanol was used as flushing Solution. The 
retention times for the drug and internal standard were 
0.95 min. Dissolution test apparatus (Labindia, India) was 
used to assess the dissolution behavior and release of MT 
from tablets.
Preparation of standard and working solutions
A drug solution was prepared by dissolving 0.08 g MT in 
methanol and the solution was taken up to 50.00 mL final 
volume to make a stock solution containing 1524.4  μg/
mL. The stock solution was diluted in a serial dilution 
using same methanol to produce a final standard solution 
of 10.00 mL containing 76.22 μg/mL MT. The stock solu-
tion for the internal solution was prepared by dissolving 
0.00108  g of Montelukast-d6 and the volume was made 
up to 100 mL with methanol to make up a stock solution 
10.101 μg/mL. The internal standard stock solution was 
diluted in a serial dilution using methanol to produce a 
final standard solution of 10.00 mL containing 0.505 μg/
mL. The working solutions for calibration, QC sample 
and IS were prepared. Prior to the extraction, each sam-
ple including: calibrators, QC samples and authentic 
samples were spiked with the IS solution (MT-d6). All 
the calibrators and the QC samples were spiked with 
IS in which 0.1 mL of plasma was spiked by 30 µl of the 
stock internal solution to get final concentration of IS of 
119.5 ng/mL. Then 1 mL of ACN was added in order to 
eliminate proteins. Then the supernatant was analyzed.
Bioanalytical validation procedure
The method was validated for its application to the anal-
ysis of MT in the biological fluids. Sampling lasted 24 h 
after drug administration in order to finalize the BE 
study.
The linearity assessment was performed using a series 
of nine standard plasma solutions previously spiked with 
MT (calibrator), were employed for constructing cali-
bration curves covering a concentration ranging from 
6.098 to 609.759  ng/mL. The accuracy and precision 
were determined by using a minimum of six replicates 
per concentration level. LOQ was determined by inject-
ing a series of diluted solutions with known concentra-
tions. In addition, stock solution stability in mobile phase 
was evaluated using two standard mixtures (along with 
internal standard). These mixtures were equivalent to the 
lower limit of quantification (LLOQ) and upper limit of 
quantification (ULOQ).
Short and long-term matrix based stabilities were 
evaluated using two MT concentrations, quality control 
low (QCL) and quality control high (QCH). Stability after 
freeze and thaw cycles was assessed using two QC sam-
ples. The QC samples were prepared to have low (QCL), 
medium (QCM) and high (QCH) concentrations (MT: 
18.293, 304.879, and 457.319  ng/mL). Four QC samples 
were incorporated with each analysis run as unknown 
Page 4 of 8Zaid et al. Clin Transl Allergy  (2015) 5:37 
samples. The drug concentration in each QC sample 
was calculated from the calibration curve and was com-
pared with the nominal concentration. The analysis run 
was accepted if at least 67 % of QC samples were within 
±15 % of the nominal values.
In vitro release of MT from film coated tablets
An HPLC method was used in order to quantify the 
amount of MT released from tablets. The used analytical 
parameters are summarized in Table 1.
The in vitro release of MT from the generic and brand 
immediate release film-coated tablets was conducted 
using USP Apparatus (II paddles) [15]. The tablets (12) 
were placed in the paddles of the dissolution apparatus 
(1 tablet/paddle) which contains 900  mL of dissolution 
media and the paddles were rotated at a speed of 50 rpm. 
The temperature was kept at 37  °C during the entire 
period of the dissolution study. Samples (5  mL) were 
taken at 5, 10, 15, and 30 min. Fresh dissolution medium 
(5 mL) was added to the paddles after each sample was 
taken. A standard was prepared of 0.011  mg/mL using 
same dissolution media. The samples (study and stand-
ard) were filtered through a 0.45  μm Millipore filter. A 
sample of 0.25  μL was injected into the HPLC appara-
tus. According to ICH guidelines and for the purpose of 
in  vitro premarketing studies, this test was repeated in 
three different dissolution media, 01  N HCl, 4.5 acetate 
buffer and 6.8 phosphate buffer, respectively.
Similarity and non similarity factors, f2 and f1, were cal-
culated in three different pH media. The f2 factor meas-
ures the closeness between two profiles and f1 measures 
difference between two profiles according to the follow-
ing equations.
where Rt and Tt are the percentages of drug dissolved 
at each time point for the reference and test products, 
respectively. An f1 value greater than 15 indicates signif-
icant dissimilarity, and an f2 value greater than 50 indi-
cates significant similarity [16, 17].
Pharmacokinetic and statistical analysis
MT plasma concentration for each of the subjects in each 
time point was reported and according to this data; MT 
plasma concentration vs. time curves were designed for 
both tablet products. The elimination rate constant (Kel) 
was calculated from the slope of the semi-logarithmic 
plot of the terminal elimination phase of the blood con-
centration–time curve. The equation t1/2  =  ln2/Kel was 
used to calculate the elimination half–life time (T1/2). The 
areas under the MT blood concentrations time curves 
from (AUC0–24) and the area to the infinity (AUC0–∞) 
were calculated by using the classical linear trapezoidal 
equation. Extrapolation to the infinity was calculated 
by dividing the last measurable MT blood concentra-
tion C24 by terminal rate constant kel. The AUC0–∞ was 
calculated according to the equation: AUC0–∞ = AUC0–
24 + AUC24–∞. The statistical method used to determine 
the BE between both formulations was based on the 
procedure known as two one-sided test; to determine if 


























Table 1 HPLC analytical parameters for MT
Mobile phase Buffer solution: dissolve 1.36 g potassium dihydrogen phosphate in 1 l 
and adjust PH to 4.0 with 20 % v/v phosphoric acid
Mix 1400 mL acetonitrile with 600 mL of buffer solution and filter 
through 0.45 µm membrane filter
Diluent Mobile phase
HPLC Waters system
Column Inertsil ODS-2 (25 cm × 4.6 mm) 5 μm
Detector 355 nm
Flow rate 1.5 mL/min
Injection volume 50 µL
Column oven temperature 40 °C
Sample cooler temperature NA
Standard solution preparation Standard solution contains: 0.02 mg/mL of montelukast
Sample solution preparation Standard solution contains: 0.02 mg/mL of montelukast
Run time 12 min
Filter Nylon filter is suitable after discarding the first 3 mL
PTFE filter is suitable after discarding the first 3 mL
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transformed average values of PK parameters measured 
after administering both the test and reference MT tab-
lets are comparable.
For the statistical analysis of data derived from this 
in BE study, one way analysis of variance (ANOVA) 
was used to assess the effect of formulations, periods, 
sequences and subjects on AUC0–24, AUC0–∞, and Cmax. 
A commercially available software package (Thermo Sci-
entific Kinetica, version 5.1) was used for the calculations.
Results
Results of validation procedures
The developed and validated LC–MS/MS method was 
found to be effective. In fact, the relationship between 
concentration and peak area ratio of MT/IS was found 
to be linear within the range 6.098–365.855  ng/mL 
for MT as shown in Fig.  1. The linear equation was 
Y = 0.00800X − 0.00970 with a correlation coefficient of 
0.998 during the course of this validation protocol. The 
method was sufficiently sensitive with LLOQ of 6.098 ng/
mL and ULOQ of 609.759  ng/mL. The mean recovery 
was 109.45, 104.44 and 101.88 % for QCL, QCM and QCH, 
respectively. The method was found to be precise and 
accurate for samples up to 1829.276 ng/mL. Short term 
stability testing (at room temperature) of MT in plasma 
and stock solution demonstrated that the drug was stable 
for up to 24 and 10 h, respectively. Freeze and thaw sta-
bility cycles showed that MT was stable after five cycles.
Results of dissolution study and similarity factor
The release of MT from the generic and brand tablets 
in the recommended three pH media was within the 
accepted levels, since f2 was higher than 50 and f1 was 
lower than 15 as reported in Table 2.
Results of pharmacokinetic study
Both MT 10 mg immediate release coated tablets, Bron-
cast® and Singulair®, were well tolerated by all treated 
subjects and they were discharged in good health. 
Figure 2 shows the plasma concentrations of both generic 
and brand products indicating that the two brands are 
interchangeable.
A summary of the PK parameters for the two products 
of MT 10 mg immediate release film coated tablets. The 
point estimates (ratios of geometric means) were 111.939, 
111.711, and 112.169 % for AUC0–24, AUC0–∞, and Cmax, 
respectively as reported in Table 3. The ANOVA results 
showed no significant statistical differences between the 
two formulations regarding variables such as cycles and 
treatment. In fact the PK parameter values lie within 
the EMA and FDA specified bioequivalence limits (80–
125  %) [18, 19]. This study demonstrated that the test 
product MT 10 mg immediate release film coated tablets 
(one Tablet) of generic versus Singulair® 10  mg imme-
diate release film coated tablets (one Tablet) were inter-
changeable after single oral dose administration of each 
product under fasting conditions. In fact, there were no 
serious or significant adverse events, with both formula-
tions being effective and sufficiently safe when adminis-
tered as a single oral dose.
Discussion
The FDA defines a brand drug as a drug marketed under 
a proprietary, trademark-protected name while a generic 
Fig. 1 Calibration curve of MT
Table 2 Summary of f2 and f1 for MT in dissolution media
Dissolution medium
0.1 N HCl pH 4.5 phosphate  
buffer
pH 6.8 phosphate 
buffer
f2 66 94 66
f1 11 6 14
Fig. 2 Plasma MT geometric mean concentration (ng/ml) versus 
time (h) curves and log plasma MT geometric mean concentration 
versus time (h) curves following a single oral dose 10 mg immediate 
release tablets
Page 6 of 8Zaid et al. Clin Transl Allergy  (2015) 5:37 
drug is similar as the brand name drug with regard to 
active ingredient, dosage form, strength, route of admin-
istration, quality, safety and efficacy as assessed from the 
PK profile, intended use, and contains the same chemi-
cal form. However, generic versions of a drug can vary 
in quality of excipients and visual appearance including 
shape, scoring, and packaging. If all the previous criteria 
are met, then the two drugs are considered to be thera-
peutically equivalent and therefore can be safely inter-
changeable [18]. During the development stage of any 
generic oral solid dosage form, several trials and tests 
are carried out in order to achieve a generic product that 
can be as safe and effective as well as the original brand. 
Dissolution study of the drug in three different kinds of 
pH media was recommended by international guidelines 
in order to predict if the generic and brand could show 
comparable in vivo activity. In fact, these tests could be 
a very useful indicator as premarketing marker for each 
batch of oral solid drug formulation and they can be used 
as a biowaiver for in vivo BE studies which were assessed 
for the initial produced batch. In this contest, the results 
of dissolution showed that the generic product was com-
parable with the original brand. In fact, f2 and f1 were 
within the recommended criteria of biowaiver studies for 
MT at pH 1.2, 4.5 and 6.8 (Table 2).
Regarding the BE studies, several previous studies 
have tested the bioequivalence of new generic MT tab-
lets or other dosage forms as granules and disintegrat-
ing tablets [20–23]. The PK values of our BE study were 
compared with similar studies that have been conducted 
on other populations [20, 24, 25]. It was interesting to 
find out that our PK values were in accordance with most 
of these values. However, one of these studies showed 
PK values lower than others as reported in Table 4 [26]. 
While some researchers suggest dealing with such issues 
by implementing personalized drug therapy, based on 
pharmacogenomic analysis for individual patients [27]. 
This would be costly and time consuming; we suggest 
using the PK parameters among different populations as 
a tool in order to adjust the recommended dose for every 
population accordingly. Such measures can maximize 
the therapeutic effects and minimize the toxic/adverse 
effects.
The main objective of this study was to assess the bio-
availability of MT 10 mg immediate release tablets pro-
duced by Avalon Pharma, versus the reference MT 10 mg 
(Singulair® immediate release coated) produced by Sharp 
Merck Dohme. The two dosage forms were orally admin-
istered to 31 fasting male volunteers in order to elimi-
nate the interference of food on drug absorption. The 
validated LC–MS method described above was utilized 
for quantification of MT 10 mg. Analytical method was 
successfully applied for PK studies. In fact, all valida-
tion parameters were carried out according to the ICH 
guidelines and they were within the accepted criteria as 
reported in Table 2. Regarding the efficacy of the generic 
product, statistical comparison of the main PK parame-
ters, AUC0–24, AUC0–∞, Cmax and Tmax clearly showed the 
Table 3 Summary of calculated PK parameters
Parameters (unit) Test montelukast Reference singular®
Efficacy results summary
 As geometric means (ranged for) Cmax and AUCRatio
  Cmax (ng/mL) 428.910 381.900
176.680 783.900 80.000 792.150
  AUC0→Last (ng h/mL) 2731.650 2437.870
1386.330 6884.470 682.170 7495.260
  AUC0→inf (ng h/mL) 2825.270 2526.380
1445.510 7597.020 737.910 7963.160
 As medians (ranges) for Tmax, and t1/2
  Tmax (h) 3.50 3.50
2.00 6.00 1.50 5.00
  t1/2 (h) 4.10 4.49
2.42 6.36 2.20 5.71
Parameter Point estimate (ratio of geometric mean %) Lower limit % Upper limit % CV %
Bioequivalence results summary
 Cmax 112.169 101.447 124.024 23.58660
 AUC0→Last 111.939 101.285 123.714 23.47754
 AUC0→inf 111.711 101.119 123.413 23.38104
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inexistence of a significant difference between test and 
reference tablets, in any of the assessed PK parameters. 
The achieved values were in accordance with the FDA 
and EMEA requirements for bioequivalence of generic 
drugs since the AUC0–24, AUC0–∞, and Cmax mean ratios 
are within the 80–125 % interval [18, 19].
Several clinical studies have highlighted the efficacy of 
Singulair® immediate release coated tablets in the treat-
ment of asthma in both adults and children, and for the 
symptomatic relief of allergic rhinitis [28–32]. Recently, 
Fey and et  al. evaluated the efficacy and safety of mon-
telukast 4  mg oral granules (Sandoz generic relative to 
Singulair® mini). The extrapolated PK values were close 
to our results; however, the author did not specify the 
race of subjects that have been used in his study [33]. 
Accordingly, we invite authors of similar studies to spec-
ify the race of the population underlying bioavailability 
and BE studies in order to see if a dose adjustment could 
be taken into consideration for better efficacy and safety. 
Given the BE demonstrated for Broncast® 10 mg imme-
diate release coated tablets, this product is expected to 
be equally efficacious and well-tolerated. Safety is very 
important factor in selecting a suitable therapy, in this 
study the administered drugs were tolerated and all the 
participated volunteers completed the whole study with-
out showing any sign of adverse effect and released in 
good health. Accordingly, this product offers a cheap, safe 
and effective treatment option for subjects with asthma 
or seasonal/perennial allergic rhinitis.
Conclusion
The statistical analysis of the results which carried out on 
AUC0–24, AUC0–∞ and Cmax using the ANOVA method 
dimonstrated that the test tablets (10 mg MT immediate 
release coated tablets) produced by Avalon Pharma and 
the reference brand tablets (Singulair® 10  mg immedi-
ate release coated tablet) are bioequivalent, since they 
release equivalent quantities of active ingredient to the 
systemic circulation at equivalent rates for both AUC0–24 
and Cmax ratios within the 80–125  % interval proposed 
by FDA and the EMA agency. These results showed that 
the new generic tablets are clinically effective and can be 
safely interchanged with the original brand. Moreover, 
the release of MT from tablets in the selected pH media 
could be used as a useful premarketing quality control 
parameter in order to guarantee same efficacy and safety 
of each produced batch of this product.
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